Vermillion CEO Gail Page to step down
This article was originally published in Clinica
Diagnostics specialist Vermillion has started looking for a successor to president and CEO Gail Page after announcing that she will leave the company. The firm, which is seeking new leadership for its commercial phase of development, hopes to find a replacement by September. Ms Page has led Vermillion since 2004; during this time, the firm has seen its OVA1 ovarian cancer blood test approved by the US FDA (www.clinica.co.uk, 16 September 2009) and launched by partner Quest Diagnostics (www.clinica.co.uk, 10 March 2010). She was also "fundamental" in developing the relationship with Quest, and helped Vermillion raise over $110m in funding. Ms Page has resigned from the board of directors, but will continue to head up the company until her successor is found.